Rifaximin in the treatment of infectious diarrhea

Charles D Ericsson1, Herbert L DuPont

  • 1Department of Internal Medicine and Division of Infectious Diseases, University of Texas Houston Medical School, Houston, TX 77030, USA. Charles.D.Ericsson@uth.tmc.edu

Chemotherapy
|April 28, 2005
PubMed

Insights

Rifaximin is an ideal treatment for infectious diarrhea due to its broad-spectrum activity and non-absorbable nature. This profile ensures efficacy and safety, minimizing resistance development for bacterial diarrhea treatment.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Infectious diarrhea poses a significant health challenge, necessitating effective and safe antimicrobial agents.
  • Current treatments like fluoroquinolones have limitations, especially in specific patient populations.

Purpose of the Study:

  • To evaluate rifaximin as an ideal agent for treating infectious diarrhea.
  • To assess its efficacy, safety, and resistance profile against enteropathogens.

Main Methods:

  • Review of clinical trials and pharmacological data on rifaximin.
  • Analysis of rifaximin's activity against a broad range of enteropathogens.
  • Assessment of its non-absorbable properties and impact on resistance.

Main Results:

  • Rifaximin demonstrates excellent activity against a wide spectrum of enteropathogens.
  • Its non-absorbable nature leads to a favorable side effect profile and low resistance emergence.
  • Clinical trials confirm high efficacy in treating bacterial diarrhea.

Conclusions:

  • Rifaximin is a highly effective and safe option for infectious diarrhea, particularly for patients where fluoroquinolones are contraindicated.
  • Its targeted action and low resistance potential support its sustained utility in treating enteric infections.

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...